Filtered By:
Vaccination: Meningitis Vaccine
This page shows you your search results in order of relevance. This is page number 19.
Order by Relevance | Date
Total 2891 results found since Jan 2013.
Adverse events following yellow fever vaccination in immunocompromised persons
Rev Inst Med Trop Sao Paulo. 2021 Mar 1;63:e13. doi: 10.1590/S1678-9946202163013. eCollection 2021.ABSTRACTThis observational retrospective study conducted during an yellow fever (YF) outbreak in Sao Paulo, Brazil, in 2017-2018, describes adverse events (AE) following YF vaccination of immunocompromised persons. Risks and benefits of vaccination were individually evaluated by physicians. AE were assessed by phone call or electronic mail, 14 to 90 days after vaccination. Three hundred and eighty one immunocompromised persons received a full-dose of YF vaccine. Their age ranged from 1.4 to 89.3 years (median 50.8 years); 53%...
Source: Revista do Instituto de Medicina Tropical de Sao Paulo - March 3, 2021 Category: Tropical Medicine Authors: Amanda Nazareth Lara Karina Takesaki Miyaji Karim Yaqub Ibrahim Marta Heloisa Lopes Ana Marli Christovam Sartori Source Type: research
Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020
This report compiles and summarizes all recommendations from CDC's Advisory Committee on Immunization Practices (ACIP) for use of meningococcal vaccines in the United States. As a comprehensive summary and update of previously published recommendations, it replaces all previously published reports and policy notes. This report also contains new recommendations for administration of booster doses of serogroup B meningococcal (MenB) vaccine for persons at increased risk for serogroup B meningococcal disease. These guidelines will be updated as needed on the basis of availability of new data or licensure of new meningococcal ...
Source: MMWR Recomm Rep - January 8, 2021 Category: Epidemiology Authors: Sarah A Mbaeyi Catherine H Bozio Jonathan Duffy Lorry G Rubin Susan Hariri David S Stephens Jessica R MacNeil Source Type: research
Adverse events following yellow fever vaccination in immunocompromised persons
Rev Inst Med Trop Sao Paulo. 2021 Mar 1;63:e13. doi: 10.1590/S1678-9946202163013. eCollection 2021.ABSTRACTThis observational retrospective study conducted during an yellow fever (YF) outbreak in Sao Paulo, Brazil, in 2017-2018, describes adverse events (AE) following YF vaccination of immunocompromised persons. Risks and benefits of vaccination were individually evaluated by physicians. AE were assessed by phone call or electronic mail, 14 to 90 days after vaccination. Three hundred and eighty one immunocompromised persons received a full-dose of YF vaccine. Their age ranged from 1.4 to 89.3 years (median 50.8 years); 53%...
Source: Revista do Instituto de Medicina Tropical de Sao Paulo - March 3, 2021 Category: Tropical Medicine Authors: Amanda Nazareth Lara Karina Takesaki Miyaji Karim Yaqub Ibrahim Marta Heloisa Lopes Ana Marli Christovam Sartori Source Type: research
Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020
This report compiles and summarizes all recommendations from CDC's Advisory Committee on Immunization Practices (ACIP) for use of meningococcal vaccines in the United States. As a comprehensive summary and update of previously published recommendations, it replaces all previously published reports and policy notes. This report also contains new recommendations for administration of booster doses of serogroup B meningococcal (MenB) vaccine for persons at increased risk for serogroup B meningococcal disease. These guidelines will be updated as needed on the basis of availability of new data or licensure of new meningococcal ...
Source: MMWR Recomm Rep - January 8, 2021 Category: Epidemiology Authors: Sarah A Mbaeyi Catherine H Bozio Jonathan Duffy Lorry G Rubin Susan Hariri David S Stephens Jessica R MacNeil Source Type: research
Synthetic Analogs of < em > Streptococcus pneumoniae < /em > Capsular Polysaccharides and Immunogenic Activities of Glycoconjugates
Russ J Bioorg Chem. 2021;47(1):1-25. doi: 10.1134/S1068162021010076. Epub 2021 Mar 20.ABSTRACTStreptococcus pneumoniae is a Gram-positive bacterium (pneumococcus) that causes severe diseases in adults and children. It was established that some capsular polysaccharides of the clinically significant serotypes of S. pneumoniae in the composition of commercial pneumococcal polysaccharide or conjugate vaccines exhibit low immunogenicity. The review considers production methods and structural features of the synthetic oligosaccharides from the problematic pneumococcal serotypes that are characterized with low immunogenicity due ...
Source: Bioorganic Chemistry - March 29, 2021 Category: Chemistry Authors: M L Gening E A Kurbatova N E Nifantiev Source Type: research
Adverse events following yellow fever vaccination in immunocompromised persons
Rev Inst Med Trop Sao Paulo. 2021 Mar 1;63:e13. doi: 10.1590/S1678-9946202163013. eCollection 2021.ABSTRACTThis observational retrospective study conducted during an yellow fever (YF) outbreak in Sao Paulo, Brazil, in 2017-2018, describes adverse events (AE) following YF vaccination of immunocompromised persons. Risks and benefits of vaccination were individually evaluated by physicians. AE were assessed by phone call or electronic mail, 14 to 90 days after vaccination. Three hundred and eighty one immunocompromised persons received a full-dose of YF vaccine. Their age ranged from 1.4 to 89.3 years (median 50.8 years); 53%...
Source: Revista do Instituto de Medicina Tropical de Sao Paulo - March 3, 2021 Category: Tropical Medicine Authors: Amanda Nazareth Lara Karina Takesaki Miyaji Karim Yaqub Ibrahim Marta Heloisa Lopes Ana Marli Christovam Sartori Source Type: research
Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020
This report compiles and summarizes all recommendations from CDC's Advisory Committee on Immunization Practices (ACIP) for use of meningococcal vaccines in the United States. As a comprehensive summary and update of previously published recommendations, it replaces all previously published reports and policy notes. This report also contains new recommendations for administration of booster doses of serogroup B meningococcal (MenB) vaccine for persons at increased risk for serogroup B meningococcal disease. These guidelines will be updated as needed on the basis of availability of new data or licensure of new meningococcal ...
Source: MMWR Recomm Rep - January 8, 2021 Category: Epidemiology Authors: Sarah A Mbaeyi Catherine H Bozio Jonathan Duffy Lorry G Rubin Susan Hariri David S Stephens Jessica R MacNeil Source Type: research
Synthetic Analogs of < em > Streptococcus pneumoniae < /em > Capsular Polysaccharides and Immunogenic Activities of Glycoconjugates
Russ J Bioorg Chem. 2021;47(1):1-25. doi: 10.1134/S1068162021010076. Epub 2021 Mar 20.ABSTRACTStreptococcus pneumoniae is a Gram-positive bacterium (pneumococcus) that causes severe diseases in adults and children. It was established that some capsular polysaccharides of the clinically significant serotypes of S. pneumoniae in the composition of commercial pneumococcal polysaccharide or conjugate vaccines exhibit low immunogenicity. The review considers production methods and structural features of the synthetic oligosaccharides from the problematic pneumococcal serotypes that are characterized with low immunogenicity due ...
Source: Bioorganic Chemistry - March 29, 2021 Category: Chemistry Authors: M L Gening E A Kurbatova N E Nifantiev Source Type: research
Adverse events following yellow fever vaccination in immunocompromised persons
Rev Inst Med Trop Sao Paulo. 2021 Mar 1;63:e13. doi: 10.1590/S1678-9946202163013. eCollection 2021.ABSTRACTThis observational retrospective study conducted during an yellow fever (YF) outbreak in Sao Paulo, Brazil, in 2017-2018, describes adverse events (AE) following YF vaccination of immunocompromised persons. Risks and benefits of vaccination were individually evaluated by physicians. AE were assessed by phone call or electronic mail, 14 to 90 days after vaccination. Three hundred and eighty one immunocompromised persons received a full-dose of YF vaccine. Their age ranged from 1.4 to 89.3 years (median 50.8 years); 53%...
Source: Revista do Instituto de Medicina Tropical de Sao Paulo - March 3, 2021 Category: Tropical Medicine Authors: Amanda Nazareth Lara Karina Takesaki Miyaji Karim Yaqub Ibrahim Marta Heloisa Lopes Ana Marli Christovam Sartori Source Type: research
Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020
This report compiles and summarizes all recommendations from CDC's Advisory Committee on Immunization Practices (ACIP) for use of meningococcal vaccines in the United States. As a comprehensive summary and update of previously published recommendations, it replaces all previously published reports and policy notes. This report also contains new recommendations for administration of booster doses of serogroup B meningococcal (MenB) vaccine for persons at increased risk for serogroup B meningococcal disease. These guidelines will be updated as needed on the basis of availability of new data or licensure of new meningococcal ...
Source: MMWR Recomm Rep - January 8, 2021 Category: Epidemiology Authors: Sarah A Mbaeyi Catherine H Bozio Jonathan Duffy Lorry G Rubin Susan Hariri David S Stephens Jessica R MacNeil Source Type: research
Synthetic Analogs of < em > Streptococcus pneumoniae < /em > Capsular Polysaccharides and Immunogenic Activities of Glycoconjugates
Russ J Bioorg Chem. 2021;47(1):1-25. doi: 10.1134/S1068162021010076. Epub 2021 Mar 20.ABSTRACTStreptococcus pneumoniae is a Gram-positive bacterium (pneumococcus) that causes severe diseases in adults and children. It was established that some capsular polysaccharides of the clinically significant serotypes of S. pneumoniae in the composition of commercial pneumococcal polysaccharide or conjugate vaccines exhibit low immunogenicity. The review considers production methods and structural features of the synthetic oligosaccharides from the problematic pneumococcal serotypes that are characterized with low immunogenicity due ...
Source: Bioorganic Chemistry - March 29, 2021 Category: Chemistry Authors: M L Gening E A Kurbatova N E Nifantiev Source Type: research
Adverse events following yellow fever vaccination in immunocompromised persons
Rev Inst Med Trop Sao Paulo. 2021 Mar 1;63:e13. doi: 10.1590/S1678-9946202163013. eCollection 2021.ABSTRACTThis observational retrospective study conducted during an yellow fever (YF) outbreak in Sao Paulo, Brazil, in 2017-2018, describes adverse events (AE) following YF vaccination of immunocompromised persons. Risks and benefits of vaccination were individually evaluated by physicians. AE were assessed by phone call or electronic mail, 14 to 90 days after vaccination. Three hundred and eighty one immunocompromised persons received a full-dose of YF vaccine. Their age ranged from 1.4 to 89.3 years (median 50.8 years); 53%...
Source: Revista do Instituto de Medicina Tropical de Sao Paulo - March 3, 2021 Category: Tropical Medicine Authors: Amanda Nazareth Lara Karina Takesaki Miyaji Karim Yaqub Ibrahim Marta Heloisa Lopes Ana Marli Christovam Sartori Source Type: research
Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020
This report compiles and summarizes all recommendations from CDC's Advisory Committee on Immunization Practices (ACIP) for use of meningococcal vaccines in the United States. As a comprehensive summary and update of previously published recommendations, it replaces all previously published reports and policy notes. This report also contains new recommendations for administration of booster doses of serogroup B meningococcal (MenB) vaccine for persons at increased risk for serogroup B meningococcal disease. These guidelines will be updated as needed on the basis of availability of new data or licensure of new meningococcal ...
Source: MMWR Recomm Rep - January 8, 2021 Category: Epidemiology Authors: Sarah A Mbaeyi Catherine H Bozio Jonathan Duffy Lorry G Rubin Susan Hariri David S Stephens Jessica R MacNeil Source Type: research
